title: Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants.
authors.forename: Agnieszka I
authors.initials: AI
authors.lastname: Mazur-Bialy
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Zdebska
authors.forename: Ewa
authors.initials: E
authors.lastname: Wypasek
authors.forename: Anetta
authors.initials: A
authors.lastname: Undas
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D005091:Exons; D005260:Female; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D005838:Genotype; D006239:Haplotypes; D006470:Hemorrhage / Q000150:complications / Q000235:genetics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D006899:Mixed Function Oxygenases / Q000235:genetics*; D009025:Morpholines / Q000627:therapeutic use; D009154:Mutation; D011044:Poland; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use; D014812:Vitamin K / Q000037:antagonists & inhibitors*; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000008:administration & dosage
chemical_list: D000925:Anticoagulants; D009025:Morpholines; D013876:Thiophenes; D014812:Vitamin K; D014859:Warfarin; D000069552:Rivaroxaban; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases